<DOC>
	<DOCNO>NCT02976142</DOCNO>
	<brief_summary>The purpose study determine whether intraperitoneal immunotherapy ( interleykin-2 - human cytokine reaction activator ) systemic chemotherapy effective systemic chemotherapy alone patient gastric cancer verify free cancer cell abdominal cavity improve long term outcomes overall survival surgical treatment .</brief_summary>
	<brief_title>The Efficacy Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone Patients With Positive Wash Cytology Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>ECOG 02 Histologically proven gastric cancer T23 N+ , T4a N ( 0 , + ) free cancer cell abdominal cavity macroscopic canceromathosis distant metastasis ( TNM classification 7th edition ) Histological form : gastric adenocarcinoma signet ring cancer Blood characteristic ( creatinine &lt; 150 mg/l , total bilirubin &lt; 50 mkmol/l , neutrophils &lt; 1500/mkl , hemoglobin &gt; 90 g/l , thrombocytes &gt; 100000/mkl ) Clinically apparent distant metastasis ( besides free cancer cell ) Synchronic metachronic malignant tumor Previous systemic surgical combine therapy gastric cancer Complications gastric cancer ( obstruction 01 GOOSS scale and/or gastric bleeding ) Adhesions abdominal cavity Gastrooesophageal junction cancer gastric cancer spread oesophagus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>gastric cancer , metastatic</keyword>
	<keyword>positive wash cytology</keyword>
	<keyword>neoadjuvant intraperitoneal immunotherapy</keyword>
</DOC>